Cellectis S.A. - American Depositary Shares — 현금 흐름 (NASDAQ:CLLS) | MetaTrader

전체 차트 열기 Full chart

Financials

개요 성명 통계

영업활동으로 인한 현금 80.26 M104.56 M87.44 M24.75 M22.99 M39.4 M — 투자 활동으로 인한 현금 54.34 M7.28 M2.76 M15.51 M102.81 M29.48 M — 재무활동으로 인한 현금 27.32 M47.52 M1.15 M82.86 M89.11 M16.76 M — 잉여 현금 흐름 80.26 M104.56 M87.44 M24.75 M22.99 M39.4 M —

Cellectis S.A. - American Depositary Shares

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

뉴스

셀렉티스(CLLS) 주식, 제프리스 ’매수’ 등급으로 커버리지 개시

Jefferies assumes coverage on Cellectis stock with Buy rating

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

Clear Street, Cellectis에 ’매수’ 등급 제시… CAR-T 잠재력 주목

Clear Street initiates Cellectis stock with Buy rating on CAR-T potential

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS)

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Allogene Therapeutics (NASDAQ:ALLO), Cellectis (NASDAQ:CLLS)

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Argo Blockchain (NASDAQ:ARBK), Ascent Solar Technologies (NASDAQ:ASTI)

Allogene, 유리한 중재 판결 후 주가 상승

Allogene, 암 치료제 통제권 재확인 중재 판정

Allogene stock rises after favorable arbitration ruling reaffirms therapy rights

Cellectis, Servier 라이선스 계약 일부 종료 중재 판결